---
title: Improve walking with robotic treadmill
nct_id: NCT04087031
phase: NA
status: RECRUITING
sponsor: Istituto Nazionale di Ricovero e Cura per Anziani
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT04087031"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04087031"
last_fetched: "2026-05-10T14:07:35.516Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking with robotic treadmill

**Goal (in five words):** Improve walking with robotic treadmill

**Official Title:** Assistive Robotic in the Elderly: Innovative Models in the Rehabilitation of the Elderly With Parkinson's Disease Through Technological Innovation

**Trial ID:** [NCT04087031](https://clinicaltrials.gov/study/NCT04087031)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Istituto Nazionale di Ricovero e Cura per Anziani
- **Target Enrollment:** 195 participants
- **Start Date:** 2019-12-03
- **Completion Date:** 2026-12-31
- **Conditions:** Parkinson Disease, Frail Elderly, Robotic Devices in Rehabilitation
- **Interventions:** control arm, virtual reality games, robotic treadmill
- **Intervention Types:** OTHER

## Summary For Families

The goal is to help frail older people with Parkinson's improve walking, balance, and independence, and to reduce falls and mobility-related dependence. The approach uses a robotic treadmill that supports and guides walking while interactive virtual reality games prompt stepping, weight shifts, and cognitive engagement to retrain gait patterns and build endurance; participants keep their usual Parkinson's medications but must have a stable drug regimen for at least one month. Looking for people 65 and older with mild to moderate Parkinson's, Hoehn and Yahr stage 1 to 3, reduced walking ability, ability to give consent, and no severe dementia or uncontrolled cardiac, autonomic, seizure, or other serious illnesses.

## Eligibility

- **Minimum age:** 65 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Hoen and Yahr scale: 1-3 stage
* FAC ≤ 2
* Ranking scale score ≤ 3
* Stability of drug treatment for at least 1 month
* Geriatric Depression Scale 5-items: negative

Exclusion Criteria:

* Concomitant participation in other studies
* Lack of written informed consent
* Clinical dementia rating (CDR) score ≥ 3
* History of syncopal episodes, epilepsy and vertigo not controlled pharmacologically
* Serious dysfunction of the autonomic system
* Severe behavioral syndromes not compensated by drugs
* Concurrent neurological diseases
* Severe systemic diseases with life expectancy \< 1 year
* Patients unable to follow up.
```

## Locations (2)

- IRCCS INRCA Hospital, Ancona, Italy _(43.6072, 13.5103)_
  - Elvira Maranesi — (CONTACT) — e.maranesi@inrca.it
  - Giovanni R Riccardi, MD — (PRINCIPAL_INVESTIGATOR)
- IRCCS INRCA Hospital, Fermo, Italy _(43.1630, 13.7227)_
  - Valentina Di Donna — (CONTACT) — v.didonna@inrca.it
  - Pietro Scendoni, MD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Roberta Bevilacqua — (CONTACT) — 00390718004767 — r.bevilacqua@inrca.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT04087031*  
*HTML version: https://parkinsonspathways.com/trial/NCT04087031*  
*Source data: https://clinicaltrials.gov/study/NCT04087031*